Thymosin Beta-4 — a 43-amino acid synthetic peptide derived from the naturally occurring thymus protein. Known for its role in cell migration, blood vessel formation, and tissue repair signaling. Short plasma half-life with prolonged cellular activity.
TB-500 is a synthetic version of the active region of Thymosin Beta-4, a protein first isolated from the thymus gland that is present in virtually all human and animal cells. The peptide consists of 43 amino acids and plays a central role in actin regulation — the protein responsible for cell structure, movement, and division.
What makes TB-500 distinctive in pharmacokinetic terms is the disconnect between its short plasma half-life (approximately 2 hours) and its prolonged biological activity. Once TB-500 reaches target tissues, it upregulates actin expression and promotes cellular migration processes that continue well beyond the peptide's clearance from the bloodstream. This is why weekly or twice-weekly dosing remains effective despite rapid plasma elimination.
TB-500 is one of the most widely researched healing peptides, with observed effects on angiogenesis (new blood vessel formation), inflammation modulation, and extracellular matrix remodeling. It is frequently stacked with BPC-157, as the two peptides operate through complementary mechanisms.
TB-500 exerts its effects primarily through interaction with the actin-sequestering protein system. By binding to G-actin monomers, it promotes actin polymerization and the formation of new cellular structures necessary for tissue repair.
TB-500 upregulates the expression of actin, which drives cell migration, wound closure, and the formation of new tissue structures. This is the peptide's primary mechanism and explains its broad tissue repair effects.
The peptide promotes the formation of new blood vessels from existing vasculature. Improved blood supply to damaged areas supports nutrient delivery and waste removal during tissue repair processes.
TB-500 modulates inflammatory responses by influencing cytokine release patterns. This creates a tissue environment more conducive to repair rather than chronic inflammation.
Unlike peptides that act primarily at the injection site, TB-500 has been observed to distribute systemically following subcutaneous administration. This means the peptide can reach distant tissues, which is why injection site proximity to the target area is considered less critical than with some other peptides.
Understanding TB-500's pharmacokinetic profile requires distinguishing between plasma kinetics and tissue-level activity. The peptide is rapidly absorbed and cleared from circulation, but its downstream effects persist substantially longer.
| Parameter | Value | Notes |
|---|---|---|
| Plasma Half-Life | ~2 hours | Rapid clearance from circulation |
| Bioavailability (SubQ) | ~95% | Excellent absorption from SubQ depot |
| Time to Peak | ~30 minutes | Rapid absorption post-injection |
| Cellular Activity Duration | ~168 hours | Actin upregulation persists 5-7 days |
| Route | Subcutaneous | Standard administration route |
| Molecular Weight | 4,921 Da | 43 amino acid sequence |
| Steady State (Cellular) | ~2-3 weeks | Based on tissue accumulation pattern |
TB-500's therapeutic activity is driven by its tissue-level effects — particularly actin upregulation — rather than its plasma concentration. Once the peptide triggers cellular signaling cascades, those processes continue independently of circulating peptide levels. This is why dosing 2-3 times per week is effective despite the 2-hour plasma half-life.
TB-500 protocols typically follow a biphasic approach: an initial loading phase at higher weekly doses followed by a reduced maintenance phase. This pattern reflects the peptide's tissue accumulation dynamics.
When TB-500 is combined with BPC-157, many protocols maintain both compounds at their standard doses. BPC-157 is typically dosed daily (250-500 mcg/day SubQ), while TB-500 follows the loading/maintenance schedule above. The two compounds are generally administered at separate injection sites.
TB-500 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection. Proper reconstitution preserves peptide integrity and ensures accurate dosing.
Gather the TB-500 vial (typically 5 mg), bacteriostatic water, alcohol swabs, and an insulin syringe. Allow the vial to reach room temperature if previously refrigerated.
Wipe the rubber stopper of both the TB-500 vial and the bacteriostatic water vial with an alcohol swab. Allow to air dry for a few seconds.
Draw 2 mL of bacteriostatic water into the syringe. This yields a concentration of 2.5 mg/mL with a 5 mg vial — meaning each 0.1 mL (10 units on an insulin syringe) contains 250 mcg.
Insert the needle into the TB-500 vial and direct the stream of bacteriostatic water against the glass wall — not directly onto the powder. Add slowly to avoid damaging the peptide.
Allow the powder to dissolve naturally by gently swirling the vial. Do not shake. The solution should become clear within 1-2 minutes. If particles remain, let the vial sit in the refrigerator — they will dissolve over time.
Store the reconstituted vial in the refrigerator at 2-8°C. Use within 3-4 weeks. For longer storage, unreconstituted powder can be kept frozen.
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. For a 2.5 mg dose, draw 1 mL (100 units on a standard insulin syringe). Use Milligram's built-in reconstitution calculator for any vial size and desired dose.